Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aditxt Inc ADTX

Healthcare Biotechnology
Aditxt, Inc. is a biotech company focused on discovering, developing, and deploying health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc... see more

Recent & Breaking News (NDAQ:ADTX)

Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)

Business Wire April 2, 2024

Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023

PR Newswire March 27, 2024

For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy

PR Newswire March 7, 2024

Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023

PR Newswire February 1, 2024

Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap(TM) and NeuroEEG(TM) for Telehealth and Tele-neurology Applications

Business Wire January 30, 2024

Aditxt, Inc.'s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.'s Proprietary Mitomic(TM) Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million

Business Wire January 8, 2024

Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

Business Wire January 5, 2024

Aditxt, Inc. Regains Compliance with Nasdaq Stockholders' Equity Requirement

Business Wire January 2, 2024

Aditxt Announces $6 Million Private Placement Priced At-The-Market under Nasdaq Rules

Business Wire December 29, 2023

Lifshitz Law PLLC Announces Investigations of EGLE, ICVX, ADTX, and HOLI

Accesswire December 13, 2023

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Aditxt, Inc. Merger

Newsfile December 13, 2023

ADTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aditxt, Inc. Is Fair to Shareholders

Business Wire December 12, 2023

Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally

Business Wire December 12, 2023

Aditxt, Inc. to Present at 8th Annual Dawson James Conference

GlobeNewswire October 6, 2023

Aditxt, Inc. Announces Appointment of Ernie Lee as CEO of its Wholly-Owned Subsidiary, Pearsanta, to Lead Launch of Test2Treat.me Platform

Business Wire October 5, 2023

Aditxt, Inc. (NASDAQ: ADTX) Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference September 11th-13th, 2023

Business Wire September 8, 2023

Aditxt Announces Closing of $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

Business Wire September 6, 2023

Aditxt Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

Business Wire August 31, 2023

Aditxt, Inc. (NASDAQ: ADTX) Provides Shareholder Update and Planned Strategy for Achieving Commercial Scale

Business Wire August 18, 2023

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on August 18, 2023

Business Wire August 17, 2023